In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement with Novartis AG, potentially valued at up to $2.5 billion. This strategic alliance aims to leverage Schrödinger’s advanced computational platform to accelerate drug discovery and development across various therapeutic areas. Under the terms of the agreement, Schrödinger […]
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths to form a formidable entity in drug discovery and development. This strategic union is set to enhance their technological capabilities and expand their clinical pipeline, paving the way for more effective and affordable medicines. Key Details of […]
Owkin, a pioneering TechBio company known for combining human and artificial intelligence to tailor treatments for individual patients, has announced a strategic collaboration with Amazon Web Services (AWS) to innovate in the fields of drug discovery, clinical trial acceleration, and the development of AI diagnostics. Leveraging AWS’s global infrastructure and its secure, extensive, and reliable […]
Owkin, a pioneering TechBio company, has announced a strategic collaboration with Amazon Web Services (AWS) to innovate in the field of drug discovery, enhance clinical trials, and advance AI diagnostics. This partnership is set to leverage AWS’s global infrastructure and cloud platform capabilities to boost data operations and accelerate research in precision medicine, aiming to […]
SCIEX, a world-renowned leader in life science analytical technologies, introduced the Echo MS+ system at the Society for Laboratory Automation and Screening (SLAS) 2024 conference. This groundbreaking system integrates proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the advanced capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ […]
Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife, a leader in computational biology, today announced a significant collaboration. This partnership is set to develop a portfolio of potential therapeutics, targeting unmet medical needs in chronic diseases. The collaboration leverages Absci’s prowess in antibody design and PrecisionLife’s expertise in complex disease biology, aiming […]
Perpetual Medicines, a frontrunner in computational peptide therapeutics, recently announced an impressive $8 million seed financing round, spearheaded by Chengwei Capital. This significant financial injection is set to bolster the company’s innovative platform for peptide drug discovery, marking a new chapter in the pharmaceutical industry. Integrating AI and Computational Design in Drug Discovery The core […]
In a significant development in the realm of drug discovery, CAS, a subsidiary of the American Chemical Society, has teamed up with tech-bio front-runner Molecule.one. The focus of this strategic collaboration is the development of computer-aided synthesis design technologies. By harnessing the prowess of Molecule.one’s proprietary AI models and CAS’ vast chemical reaction content, the […]
Hewlett Packard Enterprise (HPE) has been chosen to construct the TSUBAME4.0 by the Tokyo Institute of Technology (Tokyo Tech) Global Scientific Information and Computing Center (GSIC). TSUBAME4.0 is an advanced supercomputer aimed at accelerating artificial intelligence (AI) driven scientific discoveries in fields such as medicine, materials science, climate research, and urban turbulence. Tokyo Tech is […]
German biotechnology company BioNTech has agreed to acquire 100% of the remaining InstaDeep shares for an upfront consideration of around £362 million in cash and its shares following a Series B investment in the latter in January 2022. Under the terms of the agreement, InstaDeep’s stakeholders are entitled to receive additional milestone payments of up […]